We developed a “first in class” drug, CX-5461 that inhibits RNA polymerase I transcription of ribosomal RNA genes and induces high levels of stress and growth arrest in cancer cells. CX-5461 is demonstrating promising activity in early phase clinical trials in haematologic and solid cancers.Our studies demonstrate substantial efficacy for CX-5461 in preclinical models of refractory multiple myeloma.
Importantly, CX-5461 exhibits immunomodulatory effects and signatures of enhanced anti-tumour immune activity. In this project, we aim to characterise the molecular and cellular response to CX-5461 in combination with immune-based therapies in preclinical models of multiple myeloma in vitro and in vivo.
Supervised by
